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Abstract
Aims The aims of this paper were to investigate the analytical performance of the nine prognostic scales commonly used in
heart failure (HF), in patients with dilated cardiomyopathy (DCM), and to develop a unique prognostic model tailored to DCM
patients.
Methods and results The hospital and outpatient records of 406 DCM patients were retrospectively analysed. The informa-
tion on patient status was gathered after 48.2 ± 32.0 months. Tests were carried out to ascertain the prognostic accuracy in
DCM using some of the most frequently applied HF prognostic scales (Barcelona Bio-Heart Failure, Candesartan in Heart
Failure-Assessment of Reduction in Mortality and Morbidity, Studio della Streptochinasi nell’Infarto Miocardico-Heart Failure,
Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure, Meta-Analysis Global Group in Chronic Heart
Failure, MUerte Subita en Insuficiencia Cardiaca, Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients
With Heart Failure, Seattle Heart Failure Model) and one dedicated to DCM, that of Miura et al. At follow-up, 70 DCM patients
(17.2%) died. Most analysed scores substantially overestimated the mortality risk, especially in survivors. The prognostic accu-
racy of the scales were suboptimal, varying between 60% and 80%, with the best performance from Barcelona Bio-Heart Fail-
ure and Seattle Heart Failure Model for 1–5 year mortality [areas under the receiver operating curve 0.792–0.890 (95%
confidence interval 0.725–0.918) and 0.764–0.808 (95% confidence interval 0.682–0.934), respectively].Based on our accumu-
lated data, a self-developed DCM prognostic model was constructed. The model consists of age, gender, body mass index,
symptoms duration, New York Heart Association class, diabetes mellitus, prior stroke, abnormal liver function, dyslipidaemia,
left bundle branch block, left ventricle end-diastolic diameter, ejection fraction, N terminal pro brain natriuretic peptide,
haemoglobin, estimated glomerular filtration rate, and pharmacological and resynchronisation therapy. This newly created
prognostic model outperformed the analysed HF scales.
Conclusions An analysis of various HF prognostic models found them to be suboptimal for DCM patients. A self-developed
DCM prognostic model showed improved performance over the nine other models studied. However, further validation of the
prognostic model in different DCM populations is required.
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Introduction
Modern medicine endeavours to estimate the clinical
course and prognosis for various diseases. In the field of
cardiology, many different types of prognostic scales have
been developed for numerous clinical conditions, including
acute and chronic heart failure (HF), myocardial infarction,
atrial fibrillation (AF), and pulmonary embolism. Not only
does the complexity of these scales differ, but also, more
crucially, the accuracy of their scores. Due to the preva-
lence of HF, the ever increasing number of patients
succumbing to the disease and its diverse clinical courses,
risk stratification has been the subject of research for many
years. Numerous prognostic scales have been developed
based on large groundbreaking clinical trials evaluating
thousands of patients.1–8 However, the HF population is
highly heterogeneous, including as it does three types of
HF categorized according to the ejection fraction (EF) and
two types according to HF aetiology (ischaemic and non-
ischaemic).9 Furthermore, HF prognostic scales were not
validated for any particular type of HF, such as dilated car-
diomyopathy (DCM).
It is important to note that the DCM population differs sig-
nificantly from the rest of the HF population in terms of lower
mortality rates, which can be partly explained by the patients’
younger age and fewer comorbidities.10 Therefore, scales
constructed for the general HF population may not be suit-
able for patients with DCM, especially given the fact that
these scales were created based on different patient popula-
tions, with dissimilar therapies, and before the introduction
of angiotensin-converting enzyme inhibitors (ACEIs),
beta-blockers (BBs), mineralocorticoid receptor antagonists
(MRAs), and resynchronisation therapy (CRT). There has only
been one previous analysis of the usefulness of HF prognostic
scales in DCM; this, however, was conducted on a very selec-
tive population undergoing ventricular tachycardia (VT)
ablation.11
Another issue in relation to our current knowledge of DCM
current mortality rates and prognosis in DCM population is
that they are not well defined. The reason for this is that
the available data were gathered quite a few years ago;
the mortality rate findings also vary widely (from 6% to
43%).12–28 Moreover, apart from the score created by Miura
et al. based on a Japanese cohort from the 1990s, there is no
prognostic model specific to mortality in DCM patients.22 In
addition, the Miura et al. score was created in different
therapy settings and has not been validated on a European
DCM population.
Therefore, in order to respond to this as yet unmet clinical
need, two main objectives were formulated: (i) to analyse the
accuracy of some common HF prognostic scales in our DCM
cohort and (ii) to develop a unique prognostic model tailored
to DCM patients in particular.
Methods
Study population and protocol
Between 2010 and 2018, we included 406 consecutive DCM
patients with complete baseline and follow-up data, who
underwent detailed diagnostic work-up, entailing clinical eval-
uation, a battery of laboratory tests [morphology, uric acid
and creatinine levels, electrolytes, fasting glucose, lipid pro-
file, liver enzymes, thyroid-stimulating hormone,
high-sensitive troponin T, N terminal pro brain natriuretic
peptide (NT-proBNP), C-reactive protein], electrocardiogram
(ECG), echocardiography, and coronary catheterization or
computed tomography coronary angiography.9,29,30 In addi-
tion, some patients underwent magnetic resonance imaging,
endomyocardial biopsy, and right-heart catheterization. A
similar number of patients were incorporated into the study
each year (Supporting Information, Figure S1). DCM was diag-
nosed in accordance with the current European Society of
Cardiology recommendations, based on (i) the presence of
left ventricle (LV) dilation and impaired LV systolic function
(EF < 45%) detected via echocardiogram and (ii) the exclusion
of significant coronary artery disease (CAD; by coronary an-
giogram or computer tomography of coronary arteries), pri-
mary heart valve disease (by echocardiography and/or
magnetic resonance), congenital heart disease (by echocardi-
ography and/or magnetic resonance), and severe arterial
hypertension.29,30
The investigation conforms with the principles outlined in
the Declaration of Helsinki. Prior to the study, the relevant in-
stitutional committees and the Jagiellonian University Ethical
Committee approved the study, and all patients gave their
written informed consent.
Endpoints
The endpoint was all-cause mortality. Between April and Sep-
tember 2019, information on the status of the patients was
collected through medical records and via telephone contact.
Prognostic scores analysis
Selecting from the most commonly applied prognostic scores
used in HF, we chose those designed to estimate all-cause
mortality. We decided on the following (in alphabetic order):
the Barcelona Bio-Heart Failure risk calculator 2.0 (BCN Bio-
HF), Candesartan in Heart Failure-Assessment of Reduction
in Mortality and Morbidity (CHARM), Studio della
Streptochinasi nell’Infarto Miocardico-Heart Failure (GISSI-
HF), the Eplerenone in Mild Patients Hospitalization and Sur-
vival Study in Heart Failure, Meta-Analysis Global Group in
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Chronic Heart Failure (MAGGIC), Miura et al. Score, MUerte
Subita en Insuficiencia Cardiaca (MUSIC), Organized Program
to Initiate Lifesaving Treatment in Hospitalized Patients
With Heart Failure, and the Seattle Heart Failure Model
(SHFM).1–8,22 Due to a lack of data on cardiopulmonary
exercise tests, blood urea nitrogen levels, and apolipopro-
teins, the following scores were excluded from the study:
Metabolic Exercise test data combined with Cardiac and
Kidney Indexes, Heart Failure: A Controlled Trial Investigating
Outcomes of Exercise Training, Heart Failure Survival Score,
Evaluation Study of Congestive Heart Failure and Pulmonary
Artery Catheterization Effectiveness, Acute Decompensated
Heart Failure National Registry, Get With The Guidelines-Heart
Failure Registry, Enhanced Feedback for Effective Cardiac
Treatment-Heart Failure, and the Controlled rosuvastatin multi-
national study in heart failure.
All the variables needed to calculate the mortality risk with
the selected scales were collected from patient hospital re-
cords and outpatient visits. In 163 out of 406 (40.1%) pa-
tients, available follow-up data on troponin levels were
missing, and in 296 patients (72.9%), information on uric acid
levels were absent. In those cases of patients with missing
data, in order to determine the mortality risk utilizing the
BCN Bio-HF calculator, we assigned a mean value of troponin
(13 ng/L); for the SHFM model and GISSI-HF score, we set uric
acid levels at the mean value—7.63 mg/dL; for the MUSIC
score, for the presence of elevated troponin level, 0.64 units
were assigned to patients with missing data for troponin level
(64% of the study population with available troponin level
data had elevated troponin over normal values, at 14 ng/L).
We calculated four models for the BCN Bio-HF 2.0 calculator:
(i) without troponin T and NT-proBNP levels (M0), (ii) with
NT-proBNP level (M1), (iii) with troponin T level (M2), and
(iv) with NT-proBNP and troponin T levels (M3).1 However,
due to the highest accuracy of mortality prediction [i.e.
highest area under the receiver operating curve (AUC)], only
the fourth (M3) model was used in subsequent statistical
analysis.
For the purposes of calculating the mortality risk based on
the BCN Bio-HF and SHFM models, a dedicated IT software
was designed, which entered data into the calculators avail-
able online and then inserted the results obtained regarding
mortality risk into an Excel document; mortality risks assessed
by other risk scores were calculated by formulas created in an
Excel document.
Statistical analysis
All parameters are presented as mean ± standard deviation if
continuous, or as counts and percentages in the case of cat-
egorical variables. All quantitative variables were tested for
their normal distribution of data with the Shapiro–Wilk test.
Comparisons of continuous parameters were conducted with
t-tests when normality was confirmed, or otherwise, with the
Mann–Whitney test; the χ2 test was performed for the com-
parison of qualitative parameters. AUCs were calculated to
assess the validity of prognostic models in their accuracy of
prediction for 1month and for 1, 2, 3, 4, and 5 year mortality.
The Z test was used for comparing the AUC of each prognos-
tic scale. Results were considered statistically significant
when their P value was <0.05. The Statistica package, version
13.0 (StatSoft, TIBCO Software Inc.), was used for the statisti-
cal analysis.
The development of a prognostic model in dilated
cardiomyopathy
All parameters from Table 1 were considered predictors in or-
der to fit a prediction model for time to total death. In order
to retain a sufficient number of subjects in the analysis, we
only considered variables with missing data below 25%;
therefore, troponin T and uric acid were not included in the
model. For hospitalized patients, parameters incorporated
into the model were obtained from hospital admission, un-
less otherwise indicated.
All variables with P < 0.1 for the univariable analysis were
considered candidate predictors and were included in a pre-
diction model for time to total death (Appendix). An acceler-
ated failure time model was adopted for the DCM patients’
data, and internal validation was applied. To avoid overfitting,
the model was trained and tested on two separate data sets,
randomly split into a testing and a validating sample,
encompassing 69% and 31% of patients (280 and 126 pa-
tients, respectively). The size of the testing and validation
set was chosen to ensure an appropriate number of cases
(e.g. deaths in the first year) in a test set. The application of
the 80–20 rule (325 patients in the testing set) resulted in a
testing set including no such cases, so the testing set was re-
duced in size. A sensitivity analysis on the testing set size was
conducted to make sure that the arbitrary choice of 280 pa-
tients for inclusion did not affect results (280 and 126 pa-
tients, respectively). Subsequently, the model’s performance
was compared with the BCN Bio-HF model (Supporting Infor-
mation, Table S1).
The model training included (i) choosing a distribution for
the accelerated failure time model from Weibull, exponential,
log-normal, and log-logistic; (ii) selecting variables with the
backward stepwise method; and (iii) choosing an appropriate
transformation (log, second and third power, binning) for
continuous variables. Given the good discrimination yielded
from the tested model in both the derivation and validation
samples, the data sets were collapsed and a final Weibull
parametric model was constructed based on the entire co-
hort of 406 patients. The performance metric used in the
model training stage was the mean of AUCs obtained for 1,
2, 3, 4, and 5 year mortality prediction. R software (version
3.6.1) was used for model building.
Mortality and risk stratification in dilated cardiomyopathy 2457











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2458 E. Dziewięcka et al.













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Mortality and risk stratification in dilated cardiomyopathy 2459




During a follow-up of mean 48.2 ± 32.0months, 70 (17.2%) of
the patients died: sixty-three patients due to cardiovascular
causes, six patients due to neoplasms (three patients—lung
cancer, one patient—pancreatic cancer, one patient—meso-
thelioma, and one patient—throat cancer), and one patient
owing to complications following laparotomy (Figure 1). In
terms of procedures undergone, seven patients received left
ventricular assist device implantations and thirteen patients
HTX; one patient received both procedures.
Patients who died differed from surviving patients in terms
of clinical, vital, echocardiographic, laboratory parameters,
and therapies implemented (Table 1). Indeed, surviving and
non-surviving DCM patients were differentiated by mortality
risk calculated by most of the analysed prognostic scores
(Table 2). However, most HF scales substantially over-
estimated mortality risk for surviving patients.
Diagnostic ability of heart failure prognostic
scales
All HF scales analysed in the study produced a reasonably
good performance in terms of their prognostic ability in
DCM patients (all AUCs > 0.6), with the highest accuracy
yielded by the BCN Bio-HF and SHFM calculators for 1–5 year
mortality (Figure 2).
Prognostic model construction
After an initial evaluation of the variables presented in Table
1 and the Appendix, a prognostic model was finally created.
Table 3 provides the multivariable regression model. Our cal-
culator exceeded the accuracy of all analysed scales for the
prognosis of 1 month and 1–5 years mortality risk, with
AUC of 0.915 [95% confidence interval (CI) 0.832–0.999],
0.89 (95%CI 0.812–0.968), 0.869 (95%CI 0.805–0.934), 0.873
(95%CI 0.820 0.926), 0.844 (95%CI 0.785–0.902), and 0.839
(95%CI 0.781–0.896), relatively (Figure 2).
Individual mortality risk calculator
To compute the mortality risk, an algorithm was derived from
the model. To calculate the probability of developing an
event at a specific time, the particular combination of covar-
iates should be used along with corresponding
beta-coefficients of the Weibull model:






Figure 1 Patient flowchart with the outcome. DCM, dilated cardiomyopathy.
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• AF are acceleration factors and t is the time expressed in
months.
• AF = +0.442*gender +0.01*age +0.028*BMI
0.004*(symptoms duration) 0.562*(NYHA II)
+0.046*(NYHA III) 1.398*(NYHA IV) 0.868*DM




+ 0.289*Hb 0.934*BB +1.299(ACEI/ARB/ARNI)
0.959*MRA 0.598*digoxin 0.02(furosemide daily
dosage) 1.131*(CRT-P/CRT-D).
• To calculate mortality risk, age is expressed in years, symp-
toms duration in months, BMI as kg/m2, LVEDd in mm, EF
in percent, GFR in mL/min/1.73m2, Hb in g/dL, and furose-
mide in mg/day.
• Gender is 1 if female, 0 if male.
• NYHA II/III/IV, DM, prior stroke, abnormal liver function,
dyslipidaemia, LBBB, BB, ACEI/ARB/ARNI, MRA, digoxin,
CRT-D/CRT-P = 1 if present or used, 0 otherwise.
Discussion
The main findings of the study can be summarized as follows.
First, during the 48.2 ± 32.0 months of observation, 17% out
of 406 DCM patients died. Briefly, the prognostic HF scales
under study were suboptimal as their accuracy varied be-
tween 60% and 80%. Based on the accumulated data, a
self-developed DCM prognostic model was created. External
validation of the newly created model showed the highest ac-
curacy in comparison with the other prognostic scales under
study.
Table 2 Comparison of calculated mortality risk for non-survivors and survivors dilated cardiomyopathy patients
Non-survivors (n = 70) Survivors (n = 336) P value
Follow-up time (month) 32.1 ± 26.3 51.6 ± 32.1 <0.0001
In-hospital mortality
Outcome of study population, n (%) 4 (1.0%) 402 (99%)
Mortality risk by OPTIMIZE-HF (%) 2.95 ± 2.26 2.24 ± 1.52 0.01
1-year mortality
Outcome of study population, n (%) 19 (5.5%) 345 (94.5%)
Mortality risk by MAGGIC (%) 13.91 ± 8.15 10.21 ± 5.76 <0.0001
Mortality risk by SHFM (%) 10.82 ± 16.3 5.48 ± 6.14 <0.001
Mortality risk by BCN Bio-HF (%) 15.32 ± 15.95 9.9 ± 10.51 <0.0001
2-year mortality
Outcome of study population, n (%) 32 (11.4%) 281 (88.6%)
Mortality risk by CHARM (%) 32.49 ± 24.5 25.38 ± 19.63 0.002
Mortality risk by GISSI-HF (%) 14.05 ± 10.97 11.68 ± 8.77 0.02
Mortality risk by SHFM (%) 15.23 ± 16.36 9.93 ± 10.22 <0.001
Mortality risk by BCN Bio-HF (%) 26 ± 22.18 18.96 ± 16.8 <0.0001
Mortality risk by EMPHASIS (%) 5.07 ± 1.94 4.37 ± 1.88 <0.0001
3-year mortality
Outcome of study population, n (%) 42 (17.8%) 236 (82.2%)
Mortality risk by MAGGIC (%) 35.5 ± 25.15 27.08 ± 20.6 <0.0001
Mortality risk by BCN Bio-HF (%) 27.15 ± 13.1 23.8 ± 12.31 0.009
44-month mortality
Outcome of study population, n (%) 49 (23.3%) 210 (76.7%)
Mortality risk by MUSIC (%) 45.61 ± 22.04 27.9 ± 16.83 <0.0001
4-year mortality
Outcome of study population, n (%) 52 (26.8%) 194 (73.2%)
Mortality risk by GISSI-HF (%) 24.32 ± 15.32 22.94 ± 14.98 0.36
Mortality risk by BCN Bio-HF (%) 43.59 ± 26.61 33.93 ± 22.41 0.0001
5-year mortality
Outcome of study population, n (%) 59 (39.9%) 148 (60.1%)
Mortality risk by SHFM (%) 70.31 ± 23.55 43.25 ± 24.53 <0.001
Mortality risk by BCN Bio-HF (%) 42.61 ± 26.02 23.06 ± 17.07 <0.0001
Mortality risk by Miura et al. score (%) 24.21 ± 11.87 19.43 ± 10.36 0.001
BCN Bio-HF, Barcelona Bio-Heart Failure; CHARM, Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity; EM-
PHASIS-HF, Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure; GISSI-HF, Studio della Streptochinasi
nell’Infarto Miocardico-Heart Failure; MAGGIC, Meta-Analysis Global Group in Chronic Heart Failure, MUSIC, MUerte Subita en
Insuficiencia Cardiaca; OPTIMIZE-HF, Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure;
SHFM, Seattle Heart Failure Model.
Follow-up time was presented as mean ± SD. The mortality in study population was presented as n (%). Predicted mortality was calcu-
lated based on scores presented as mean ± standard deviation.
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Overview of prognostic studies in dilated
cardiomyopathy
We identified 17 studies analysing mortality in DCM since the
1980s up to the present.12–28 The reported mortality rate var-
ied from 6% (reported by Marume et al.) to 43% (from
Sobrino-Márquez et al.). Overall, the studies differ fundamen-
tally, especially in terms of the dates (from 1978 to 2017), the
duration of observation (from 1 to over 9 years), the number
of recruited patients (from 87 to 881—on average, 350 pa-
tients—while one Japanese study looked at 1554 patients).
However, in most, the mortality rate reported after approxi-
mately 5 years was 15–25%, which is in line with our
observations.
The largest study, analysing 5 year mortality in 1554 DCM
patients, was conducted on the basis of a nationwide survey
of cardiomyopathies conducted by the Japanese Research
Committee on Idiopathic Cardiomyopathies.22 However, the
study was conducted 15 years ago before the introduction
of most modern HF therapies; for instance, ACEI, BB, and
electrotherapy were not in use. Moreover, the Japanese
study also included patients with EF over 40% and 50%
(encompassing 34% of the study population).
The enormous changes in HF therapy over the last decades
may well have led to effects in DCM mortality rates, and
therefore, more recent studies on the subject are required.27
There has been only one study focused on DCM mortality to
date conducted by Miura et al.12 However, they found a sur-
prisingly low death risk (6.2%) after a 4 year observation,
which is not consistent with our results, nor with the
subanalysis of the PARADIGM-HF study (16.8% patients had
died after 27 months).31
Comparison of heart failure prognostic scales in
dilated cardiomyopathy
We examined the eight most popular HF prognostic scales as
part of our study.1–8,22 Typically reported mortality in unse-
lected HF patients varies between 24% and 40% after approx-
imately 3 years of observation, which seems to be higher
than in DCM. The scales differed appreciably in terms of the
Figure 2 Receiver operating characteristic curves for prognosis accuracy of all scores for 1 month and 1, 2, 3, 4, and 5 year mortality with a comparison
of all the models. AUC, area under the receiver operating curve; BCN Bio-HF, Barcelona Bio-Heart Failure; CHARM, Candesartan in Heart
Failure-Assessment of Reduction in Mortality and Morbidity; DCM, dilated cardiomyopathy; EMPHASIS-HF, Eplerenone in Mild Patients Hospitalization
and Survival Study in Heart Failure; GISSI-HF, Studio della Streptochinasi nell’Infarto Miocardico-Heart Failure; MAGGIC, Meta-Analysis Global Group in
Chronic Heart Failure, MUSIC, MUerte Subita en Insuficiencia Cardiaca; OPTIMIZE-HF, Organized Program to Initiate Lifesaving Treatment in Hospital-
ized Patients With Heart Failure; SHFM, Seattle Heart Failure Model.
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general derivation cohorts and, consequently, in parameters
included in the calculation of the scores (Supporting Informa-
tion, Table S2). From the scales we looked at, only four in-
cluded HF aetiology, while patients with non-ischaemic HF
covered about half of the derivation cohorts (DCM about
10–16%). Moreover, the analysed scores differed significantly
in terms of the size of the study population, follow-up time,
and observation period; the derivation cohorts also differed,
in terms of age, sex, New York Heart Association (NYHA)
class, EF, and type of HF (five scales included both acute
and chronic HF patients, and six scales covered HF with re-
duced and preserved EF). In addition, the overall score de-
signs vary significantly with regard to the number of factors
involved (from 5 to 22), the type of parameters incorporated,
and the method for calculating mortality risk. It is also worth
noting that most of these studies did not incorporate
NT-proBNP and troponin levels, nor even pharmacotherapy,
all of which are known prognostic factors in HF and DCM.
We identified only one study that compared the accuracy
of the most popular HF prognostic scores in DCM.11 However,
the analysis of Muser et al. was conducted on a smaller (282
patients) and highly select group of DCM patients undergoing
VT ablation. The authors reported similar survival rates of
15% over 4 years and found that SHFM yielded the highest
prognostic accuracy.
In our study, the best performance (highest AUC and no
significant lack of fit) in predicting 1, 2, 3, 4, and 5 year mor-
tality was from both BCN Bio-HF and SHFM, probably due to
their advanced statistical methods (model linearity, continu-
ous variables), the large number of parameters incorporated,
including those typically associated with HF [NYHA, EF, labo-
ratory parameters, and therapy (pharmacotherapy and
CRT)], and factors also germane to DCM. The utility of most
of the analysed scales showed moderate accuracy (most
showing an AUC of 0.65–0.75) due to the overestimation of
the mortality risk in the majority of patients.
The most probable explanation for the overestimation of
the risk of death is the significantly higher mortality rate in
HF derivation cohorts than in the DCM population
(Supporting Information, Table S2). Without doubt, age is
one the strongest parameters affecting mortality risk. Typi-
cally, general HF patients are 15 to 20 years older than
DCM patients (in our study, the mean age was 54 years in
comparison with the mean age of HF cohorts i.e. 65–73 years,
a data point that was used for previously created prognostic
models). Additional factors profoundly impacting HF
Table 3 Multivariable Weibull prognostic model for death from any cause
Parameters
Acceleration factors
(AF) [95%CI] P value
Coefficient for mortality
prediction analysis
Gender (female) 1.56 [0.70–3.45] 0.28 +0.442
Age (years) 1.01 [0.99–1.04] 0.44 +0.01
BMI (kg/m2) 1.03 [0.96–1.10] 0.41 +0.028
Symptoms duration (months) 0.99 [0.99–1.00] 0.03 0.004
NYHA II 0.57 [0.18–1.78] 0.33 0.562
NYHA III 1.05 [0.33–3.37] 0.94 +0.046
NYHA IV 0.25 [0.07–0.84] 0.03 1.398
DM 0.42 [0.21–0.85] 0.02 0.868
Prior stroke 0.39 [0.17–0.90] 0.03 0.945
Abnormal liver function 0.55 [0.28–1.07] 0.08 0.601
Dyslipidaemia 1.75 [0.96–3.19] 0.07 +0.559
LBBB 0.44 [0.23–0.84] 0.01 0.816
LVEDd (mm) a 0.04 c
EF (%) 0.96 [0.93–1.00] 0.07 0.037
log10NT-proBNP 0.35 [0.18–0.67] 0.001 1.054
eGFR (mL/min) b 0.76 c
Hb (g/dl) 1.32 [1.09–1.60] 0.004 +0.289
BB 0.39 [0.12–1.31] 0.13 0.934
ACEi/ARB/ARNI 3.67 [1.67–8.06] 0.001 +1.299
MRA 0.38 [0.14–1.07] 0.07 0.959
Digoxin 0.55 [0.30–1.00] 0.05 0.598
Furosemide daily doses (mg/day) 0.99 [0.99–1.00] 0.32 0.02
CRT-P/CRT-D 0.32 [0.10–1.02] 0.05 1.131
ACEi, angiotensin-converting-enzyme inhibitors; ARB, angiotensin receptor blockers; ARNI, angiotensin receptor-neprilysin inhibitor;
BB, beta-blocker; BMI, body mass index; CRT-P/CRT-D, cardiac resynchronization therapy-pacemaker/defibrillator; DM, diabetes mellitus;
EF, ejection fraction; GFR, globular filtration rate; Hb, haemoglobin; LBBB, left bundle brunch block; LVEDd, left ventricle end-diastolic
diameter; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association class.
Model P value < 0.001. The formula for assessment of individual mortality risk is presented in the Results section. For acceleration factor
computation used in the formula, it is necessary to calculate the sum of the products of coefficients and the value of all factors included in
the table.
a1.17 [1.01–1.35] for LVEDd + 0.999 [0.998–0.999] for LVEDd2.
b1.016 [0.919–1.123] for GFR + 2.425 [<0.001–6.5105] for GFR2 and 0.165 [0.002–17.2] for GFR3.
cFor calculating the relevance of LVEDd and eGFR, the following calculation should be included: +0.154*LVEDd 0.001*LVEDd2
+0.016*eGFR +0.886*(eGFR/100)2 –1.8*(eGFR/100)3.
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prognosis are the type and number of comorbidities. Recent
studies show that elderly HF patients have typically three
(and more in most cases) clinically relevant and
outcome-affecting comorbidities. Younger DCM populations
are significantly less burdened with comorbidities, which
can also be seen in Supporting Information, Table S2. HF
aetiology is another significant influence on prognoses. HF
due to CAD constitutes the majority of HF populations in var-
ious HF randomized controlled trials and registries, while nu-
merous mechanisms causing HF development, such as acute
ischaemic injury (as in the case of myocardial infarction),
prolonged suboptimal myocardial perfusion, inflammation,
or fibrosis, impact on the poor prognosis in HF patients due
to CAD. Moreover, in the presentation of most patients with
HF, for instance, as a result of CAD, primary valvular heart dis-
eases or congenital heart diseases, there are many exacerba-
tions that significantly worsen their prognosis. In contrast,
DCM patients are rather unique in that a substantial number
of them (between 30 to 50%) undergo left ventricular reverse
remodelling (LVRR), which critically improves prognosis. Obvi-
ously, morphological and functional cardiac improvement
may be seen in HF patients of other aetiologies; however, this
is much rarer and more unpredictable in comparison with
DCM. Thus, the phenomenon of LVRR must be taken into ac-
count when studying prognoses in DCM patients. Moreover,
certain methods of treatment have a positive effect on a pa-
tient’s prognosis, especially in light of LVRR. It has been
shown that the novel pharmacotherapy angiotensin
receptor-neprilysin inhibitor (ARNI) significantly improves
prognosis via the improvement of LV function, regardless of
the HF aetiology.31 Moreover, the patient response to ther-
apy also determines outcome; for example, DCM patients re-
spond better to CRT than ischaemic HF patients. Therefore,
the mortality rate reported in the previous studies is also
probably higher due to a lack of optimal novel HF therapy;
in the derived cohorts, BBs were used in about 62% of cases
and MRA in 28% of study populations.
Furthermore, we have clearly shown that simpler HF risk
models, that is, those that are simpler in terms of the number
of parameters used and the statistical methodology
employed (such as MUSIC, CHARM), showed very poor accu-
racy for DCM patients. On the other hand, sophisticated risk
models, incorporating much larger numbers of parameters
(including continuous variables) and relying on linear statisti-
cal models, such as BCN Bio-HF and SHFM, showed much bet-
ter accuracy (70–80%) for our DCM population.
To the best of our knowledge, there has been only one
prognostic scale dedicated to DCM patients to date, that per-
formed by Miura et al.9 However, its prognostic accuracy was
not satisfactory (predicting correctly the outcome for only
about 60% of patients) probably due to the small number
of factors included—just five parameters [sex, age, NYHA, left
ventricular end-diastolic diameter (LVEDd) indexed on body
surface area, EF]—and the simple method of calculation
used, that is, numerical values attributed to the parameters
under analysis.
The development of a mortality calculator
tailored for dilated cardomyopathy
Many factors influence the mortality rate in DCM; among
these are symptom severity, functional capacity, LV remodel-
ling, the degree of impairment in left and right ventricular
contractility, LV enlargement, QRS duration, the presence of
late post-contrast enhancement in magnetic resonance imag-
ing, left bundle brunch block (LBBB) or VT, NYHA, and HF
therapy.12,16,21,22,24,26,32 However, their exact impact on
death in a multivariable model is unclear because most of
the studies identifying these factors focussed on a single spe-
cific parameter rather than investigating multivariable prog-
nostic factors. The largest study on mortality in DCM, from
Miura et al., performed a regression analysis, but their mor-
tality rate differs significantly from the other studies men-
tioned above. As far as we know, ours is the first
exploration of independent prognostic factors in such a large
cohort of DCM patients. To the best of our knowledge, we
are the first to address LVEDd as an independent mortality
predictor. Moreover, we found symptom severity and dura-
tion, diabetes mellitus, LBBB, prior stroke, haemoglobin, NT-
proBNP, and angiotensin blocker usage to be independent
prognostic factors. In contrast to the most recent discoveries
of Cannata et al. with regard to a lower mortality rate in
women, in our own analysis, gender was not found to be re-
lated to the outcome in multivariate prognostic analyses, a
finding which is in accordance with the BCN Bio-HF and SHFM
studies.33–35 Intriguingly, EF was not found to be a significant
independent prognostic factor, which is in line with the BCN
Bio-HF study, but not with the latest prognostic analysis in
HF, that is, PARADIGM-HF (Simpson et al. reported a 7% de-
crease in mortality rate for every 5% increase of EF).36 Simi-
larly, BB usage was not a crucial factor (probably due to the
high rate of use of this treatment in both survivors and
non-survivors). As in the BCN Bio-HF, we did not find other
HF therapies in the HF cohort to have any significant impact
on outcomes in DCM (via multivariate analysis).
In light of the results of the scales comparison for HF, our
own DCM prognostic calculator incorporated numerous vari-
ables and used model linearity for the calculation of mortality
risk rather than creating a simple numerical score. Having car-
ried out a detailed analysis, a calculator consisting of 21 pa-
rameters (including clinical, ECG, echocardiographic, and
laboratory parameters as well as applied therapy) emerged
as the one with the highest accuracy for mortality risk
prediction.
We report here that our own DCM model outperformed all
the other HF models under study, including BCN Bio-HF and
SHFM. Although most of the incorporated parameters in
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BCN Bio-HF and SHFM and in our model are similar, there are
also major differences that may well be responsible for the
upgraded performance of our model. Cardiac morphology
(e.g. LVEDd) is important both in the clinical course and prog-
nosis in DCM (e.g. LVRR). Therefore, uniquely, we inserted
LVEDd into our model, whereas no such parameter exists in
other models, including BCN Bio-HF and SHFM. Furthermore,
the duration of HF symptoms, which roughly reflects the on-
set of HF, also seems to be a highly relevant parameter; how-
ever, apart from CHARM and MAGGIC scores (that in any
performed less well than our model), this parameter was
not included in other models. In contrast to other models,
we included the highest number of disease-modifying thera-
pies (e.g. BBs, ACEI/ARB/ARNI, MRA, CRT-D) and other thera-
pies (digoxin, furosemide daily doses).
An example of a calculation for individualized risk
Based on the model presented here, the individual mortality
risk of a DCM patient can be calculated using the formula
from the Results section. For example, the 5 year mortality
risk of a 35-year-old male patient with DCM diagnosed
22 months ago in NYHA class II, with a normal body mass in-
dex (24 kg/m2), dyslipidaemia but with no other concomitant
disease (e.g. diabetes mellitus, prior stroke, abnormal liver
function), with QRS 90 ms in ECG, LVEDd 72 mm and EF
25% via echocardiography, Hb 14.2 g/dL, glomerular filtration
rate (GFR) 75 mL/min/1.73 m2, and NT-proBNP 1756 pg/mL
in laboratory tests, on adequate HF therapy (BB, ARNI,
MRA; without digoxin and CRT), requiring 80 mg of furose-
mide per day is 4.3%0:5trueem 10:222em e 601343:551ð Þ
1:004 
:
In contrast, a 60-year-old woman diagnosed with DCM 5 years
(60 months) ago with NYHA class III, obesity (body mass in-
dex 33 kg/m2), diabetes mellitus and dyslipidemia (without
prior stroke and abnormal liver function), with LBBB, LVEDd
65 mm and EF 35%, Hb 12 g/dL, GFR 40 mL/min/1.73m2,
and NT-proBNP 500 pg/mL, on adequate HF therapy (BB,
ARNI, MRA, digoxin; without CRT), requiring 160 mg of furo-
semide per day, has a 5-year mortality risk of 24.4%




Although the size of the current study population is relatively
large, we clearly acknowledge that the validity of any survival
analyses may be considerably diminished for the purpose of
investigating mortality in DCM, as this is a single-centre retro-
spective analysis. Although only a few patients were excluded
due to a lack of data or follow-up information, there were de-
ficiencies in the data for troponin and uric acid levels. How-
ever, this lack of data did not in any way influence the
results of the analysis of the prognostic scales. Moreover,
these parameters (troponin and uric acid levels) were not
included in our own prognostic model. However, we included
nine HF prognostic scales in our analysis, and we excluded
several commonly used ones, such as Metabolic Exercise test
data combined with Cardiac and Kidney Indexes, Evaluation
Study of Congestive Heart Failure and Pulmonary Artery Cath-
eterization Effectiveness, Enhanced Feedback for Effective
Cardiac Treatment-Heart Failure, and Heart Failure Survival
Score scores, due to the lack of data. The prognostic calcula-
tor was created based on an unambiguous endpoint—overall
mortality—and is a multiparameter model. It is the first
model of such complexity tailored to DCM patients. As with
previous studies on prognostic HF scales, which included both
stable and unstable patients, our study population represents
a mixture of stable DCM (85%) and urgently admitted pa-
tients due to HF worsening (15%).
Conclusions
The mortality rates calculated by common HF prognostic
scales (BCN Bio-HF, CHARM, GISSI-HF, Eplerenone in Mild Pa-
tients Hospitalization and Survival Study in Heart Failure,
MAGGIC, the score from Miura et al., MUSIC, Organized Pro-
gram to Initiate Lifesaving Treatment in Hospitalized Patients
With Heart Failure) vary in their results in terms of DCM sur-
vivals and non-survivals; however, their performance in prog-
nosis prediction seems to be limited for patients with DCM. A
newly developed prognostic model tailored to DCM patients
outperformed all of the scales under analysis (including
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APPENDIX
The parameters considered to be predictors were defined as
follows: weight and echocardiographic parameters were
obtained from hospital admission in stable patients or after
stabilization in the case of urgent hospitalization; the
presence of concomitant disease was established based on
patients’ medical documentation, pharmacotherapy in use,
and the results obtained during hospitalization; the presence
of abnormal liver function was defined as chronic hepatic
disease (e.g. cirrhosis) or biochemical evidence of significant
hepatic derangement (bilirubin twice the normal upper limit, in
association with aspartate or alanine aminotransferase/alkaline
phosphatase three times the normal upper limit, labile INR
without antithrombotic therapy); and pharmacological therapy
was assessed at hospital discharge.
Mortality and risk stratification in dilated cardiomyopathy 2467
ESC Heart Failure 2020; 7: 2455–2467
DOI: 10.1002/ehf2.12809
